Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Criteria for Compensation for AE Sustained in Clinical Trials Needed: JSCPT
January 21, 2002
- Foreign Firm Are Enthusiastic about Increasing Number of MRs: Survey
January 21, 2002
- NEDO Selects Technology Research Projects for Funding in 2001
January 21, 2002
- Use of Celera Genomics Database Expanding in Japan
January 21, 2002
- Pharmacy-based Pharmacists Show Sharp Increase: Medical Professional Survey
January 21, 2002
- Company Leaders Express Commitment to Reform: New Year Addresses
January 21, 2002
- Results of Survey on Clinical Studies Announced
January 21, 2002
- Meiji Seika to Concentrate on Infectious Diseases
January 21, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 21, 2002
- Kirin's Pharma Business Policy for FY2002 Announced
January 21, 2002
- Saitama Drugstore Chain Greencross-coa to Acquire Ikeno
January 21, 2002
- 2002 to Be an Exciting Year: Mr Bessho of Suzuken
January 21, 2002
- Ain Pharmaciez: Sales, Profits Show Double-digit Increases
January 21, 2002
- BDJ: BD Eclipse, Needles to Reduce Needle Stick Injuries
January 21, 2002
- Suzuken to Create New MS Image Using IT
January 21, 2002
- Hyogo's Drugstore Chain Maruzen Aims at Sales of \40 Bil.
January 21, 2002
- LDP to Create Panel to Discuss PAL
January 21, 2002
- Toho to Make Funabashi a 100%-Subsidiary
January 21, 2002
- Sumitomo Heavy Industries, GEYMS: FDG MicroLab
January 21, 2002
- Korosho to Make Full Effort to Develop Strong Drug Industry
January 21, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…